Background {#sec1}
==========

Neuroblastoma is the most common malignant extracranial solid tumor in children, accounting for 7--10% of all tumors in children \[[@B1],[@B2]\]. Neuroblastoma originates from neural crest precursor cells of the sympathetic nervous system and is mainly located on the adrenal medulla, paraspinal ganglia, and sympathetic trunk \[[@B3]\]. The outcome of neuroblastoma is affected by several factors, such as age of onset, pathology subtypes, International Neuroblastoma Staging System (INSS) stage, c-Myc status, DNA ploidy, and structural chromosomal aberrations \[[@B3]\].

Genetic factors are critically important in neuroblastoma tumorigenesis. Approximately 1% of patients have a family history of neuroblastoma, and these patients are carriers of certain gene mutations. For example, the anaplastic lymphoma kinase (*ALK*) gene and paired-like homeobox 2b (*PHOX2B*) gene have been identified as predisposing factors to familial neuroblastoma \[[@B6]\]. Evidence from genome-wide association studies (GWASs) of sporadic cases also suggests that genetic factors might be involved in the pathogenesis of neuroblastoma \[[@B9],[@B10]\]. These studies indicate an important role of genetic characteristics in the tumorigenesis of neuroblastoma. Single nucleotide polymorphisms (SNPs) or other gene mutations, such as rare mutations in the *ALK* gene at locus 2p23 for familial neuroblastoma, common SNPs in cancer susceptibility candidate 15 (*CASC15*) and neuroblastoma-associated transcript 1 (*NBAT1*) at 6p22 were found to be involved in tumor initiation of neuroblastoma, and the bos taurus BRCA1 associated RING domain 1 (*BARD1*) gene at 2q35, *IL3*, cholesterol-lowering factor (*CFL*), and lens intrinsic membrane (*LIM*) domain only 1 (*LMO1*) were found to be related to the risk of sporadic neuroblastoma.

*H19* is a paternally imprinted gene that is located at chromosome 11p15.5 near the *IGF2* gene. The expression of H19 peaks during embryogenesis and is down-regulated after birth in most tissues. Increasing evidence has revealed that H19 plays a critical role during tumorigenesis. H19 has been found to re-express during tumorigenesis in many kinds of tumors, such as breast cancer \[[@B11]\], lung cancer \[[@B12]\], invasive cervical carcinomas \[[@B13]\], esophageal cancer \[[@B14]\], and bladder cancer \[[@B15]\]. Smoking, exposure to the carcinogens, nitrosamine and diethylnitrosamine, and hypoxia are risk factors for H19 overexpression \[[@B16]\]. The up-regulation of *H19* enhances resistance of cancer cells to stress, such as genome destabilization and hypoxia \[[@B17]\].

Recently, a GWAS revealed that SNPs in *H19* are associated with cancer susceptibility \[[@B18]\], and the correlation of *H19* polymorphisms and cancers were confirmed in subsequent studies \[[@B19]\]. A study on colorectal cancer reported that the SNPs rs2839698 G\>A, rs3024270 C\>G, and rs217727 G\>A, which are located at exon 1, exon 5, and intron region of the *H19* gene, respectively, have effects on the secondary structure of *H19* \[[@B20]\], and these SNPs were found to be associated with an increased cancer risk in Chinese populations \[[@B20],[@B22]\]. However, few studies have focused on neuroblastoma. Herein, we performed a two-center hospital-based case--control study using data from 393 neuroblastoma patients and 812 control subjects to evaluate the association between the *H19* gene rs2839698, rs3024270, and rs217727 polymorphisms and neuroblastoma risk in Chinese children.

Materials and methods {#sec2}
=====================

Study subjects {#sec2-1}
--------------

The subjects enrolled were described in previous studies \[[@B28],[@B29]\]. Briefly, a total of 393 neuroblastoma patients and 812 cancer-free controls from two provinces of China were enrolled in the present study. Two hundred seventy-five neuroblastoma patients and 531 controls were recruited from the Guangzhou Women and Children's Medical Center in South China, and 118 neuroblastoma patients and 281 controls were recruited from the Henan province in North China \[[@B30],[@B31]\]. The diagnosis and clinical stages of neuroblastoma were made according to the INSS \[[@B32]\]. The healthy controls had no history of malignancies and were matched to the neuroblastoma cases in terms of age (±5 years), sex, ethnicity, and geographical region \[[@B33]\]. Both neuroblastoma patients and controls were unrelated Chinese Han individuals living in the Guangdong and Henan provinces of China. The present study was approved by the Institutional Review Board of each hospital, and written informed consent was obtained from the participants' parents or legal guardians.

SNP selection and genotyping {#sec2-2}
----------------------------

The dbSNP database and SNPinfo were used for selecting candidate SNPs. Three widely investigated SNPs (rs2839698, rs3024270, and rs217727) in the *H19* gene were studied. SNP genotyping was performed by the TaqMan real-time PCR system as previously reported \[[@B36]\]. To validate the accuracy of the genotyping results from TaqMan real-time PCR, approximately 10% of the samples were randomly selected as quality control samples and genotyped using sequencing. The concordance for the quality control samples was 100%.

Statistical analysis {#sec2-3}
--------------------

All statistical tests were two-sided, with a significance level of *P*\<0.05. All statistical analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC, U.S.A.). Two-sided *χ^2^* tests were used to analyze the demographic data and genotype frequencies. The Hardy--Weinberg equilibrium was assessed by goodness-of-*χ^2^* test. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate associations between *H19* polymorphisms and neuroblastoma susceptibility.

Results {#sec3}
=======

Associations between H19 gene polymorphisms and neuroblastoma susceptibility {#sec3-1}
----------------------------------------------------------------------------

In the present study, 392 patients and 810 controls were successfully genotyped. The genotype frequencies of all the three selected SNPs were in Hardy--Weinberg equilibrium (rs2839698, *P*=0.090; rs3024270, *P*=0.159; rs217727, *P*=0.470). The genotype frequencies of the three SNPs in the patients and controls are listed in [Table 1](#T1){ref-type="table"}. None of the three SNPs were found to be associated with an increased neuroblastoma risk in the separate analyses of each SNP or in the combined analysis on protective genotypes of the three SNPs.

###### Logistic regression analysis for the associations between *H19* polymorphisms and neuroblastoma risk

  Genotype                                  Cases (*n*=393)   Controls (*n*=810)   *P*[^1^](#T1TFN1){ref-type="table-fn"}   Crude OR (95% CI)   *P*     Adjusted OR (95% CI)[^2^](#T1TFN2){ref-type="table-fn"}   *P*[^2^](#T1TFN2){ref-type="table-fn"}
  ----------------------------------------- ----------------- -------------------- ---------------------------------------- ------------------- ------- --------------------------------------------------------- ----------------------------------------
  rs2839698 (HWE = 0.090)                                                                                                                                                                                         
  GG                                        179 (45.55)       365 (45.06)                                                   1.00                        1.00                                                      
  AG                                        175 (44.53)       373 (46.05)                                                   0.96 (0.74--1.23)   0.732   0.96 (0.75--1.24)                                         0.754
  AA                                        39 (9.92)         72 (8.89)                                                     1.11 (0.72--1.70)   0.650   1.11 (0.73--1.71)                                         0.624
  Additive                                                                         0.797                                    1.01 (0.84--1.22)   0.890   1.02 (0.84--1.23)                                         0.858
  Dominant                                  214 (54.45)       445 (54.94)          0.874                                    0.98 (0.77--1.25)   0.874   0.99 (0.77--1.26)                                         0.901
  Recessive                                 354 (90.08)       738 (91.11)          0.561                                    1.13 (0.75--1.70)   0.561   1.14 (0.75--1.71)                                         0.541
  rs3024270 (HWE = 0.159)                                                                                                                                                                                         
  CC                                        99 (25.19)        213 (26.30)                                                   1.00                        1.00                                                      
  CG                                        203 (51.65)       424 (52.35)                                                   1.03 (0.77--1.38)   0.842   1.03 (0.77--1.38)                                         0.829
  GG                                        91 (23.16)        173 (21.36)                                                   1.13 (0.80--1.60)   0.486   1.14 (0.80--1.61)                                         0.472
  Additive                                                                         0.764                                    1.06 (0.89--1.27)   0.494   1.07 (0.89--1.27)                                         0.480
  Dominant                                  294 (74.81)       597 (73.70)          0.682                                    1.06 (0.80--1.40)   0.683   1.06 (0.81--1.40)                                         0.667
  Recessive                                 302 (76.84)       637 (78.64)          0.480                                    1.11 (0.83--1.48)   0.480   1.11 (0.83--1.48)                                         0.470
  rs217727 (HWE = 0.470)                                                                                                                                                                                          
  GG                                        186 (47.33)       382 (47.16)                                                   1.00                        1.00                                                      
  AG                                        164 (41.73)       342 (42.22)                                                   0.99 (0.76--1.27)   0.907   0.98 (0.76--1.27)                                         0.888
  AA                                        43 (10.94)        86 (10.62)                                                    1.03 (0.68--1.54)   0.898   1.02 (0.68--1.53)                                         0.922
  Additive                                                                         0.979                                    1.00 (0.84--1.20)   0.970   1.00 (0.84--1.20)                                         0.997
  Dominant                                  207 (52.67)       428 (52.84)          0.956                                    0.99 (0.78--1.26)   0.956   0.99 (0.78--1.26)                                         0.932
  Recessive                                 350 (89.06)       724 (89.38)          0.865                                    1.03 (0.70--1.52)   0.864   1.03 (0.70--1.52)                                         0.884
  Combined effect of protective genotypes                                                                                                                                                                         
  0                                         258 (65.65)       551 (68.02)                                                   1.00                        1.00                                                      
  1-3                                       135 (34.35)       259 (31.98)          0.410                                    1.11 (0.86--1.44)   0.410   1.11 (0.86--1.44)                                         0.411

*χ^2^* test for genotype distributions between neuroblastoma patients and cancer-free controls.

Adjusted for age and sex.

Stratification analysis {#sec3-2}
-----------------------

We next analyzed the association of the three SNPs with neuroblastoma risk by stratification analyses ([Table 2](#T2){ref-type="table"}). Stratification analyses were conducted based on age (≤18 months, \>18 months), sex (female, male), site of origin (adrenal gland, retroperitoneal, mediastinum, other sites), and clinical stage (I+II+4s, III+IV). We found that the increased risk associated with the rs3024270 GG variant genotype was more pronounced in females (adjusted OR = 1.61, 95% CI = 1.04--2.50, *P*=0.032). Regarding the risk genotypes, no significant associations between the 1--3 risk genotypes and neuroblastoma risk were found.

###### Stratification analysis for association between *H19* genotypes and neuroblastoma susceptibility

  Variables         rs2839698 (patient/control)   Adjusted OR[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}   rs3024270 (patient/control)   Adjusted OR[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}   rs217727 (patient/control)   Adjusted OR[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}   Risk genotypes (patient/control)   Adjusted OR[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}                                          
  ----------------- ----------------------------- ------------------------------------------------ ---------------------------------------- ----------------------------- ------------------------------------------------ ---------------------------------------- ---------------------------- ------------------------------------------------ ---------------------------------------- ---------------------------------- ------------------------------------------------ ---------------------------------------- --------- -------- ------------------- -------
  Age, months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ≤18               110/276                       15/29                                            1.29 (0.66--2.50)                        0.452                         95/240                                           31/65                                    1.21 (0.74--1.97)            0.454                                            116/270                                  10/35                              0.67 (0.32--1.39)                                0.278                                    85/205    41/100   0.99 (0.64--1.54)   0.962
  \>18              243/462                       24/43                                            1.06 (0.63--1.79)                        0.830                         207/397                                          60/108                                   1.07 (0.75--1.52)            0.727                                            234/454                                  33/51                              1.25 (0.79--2.00)                                0.342                                    173/346   94/159   1.18 (0.86--1.62)   0.297
  Sex                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Female            148/317                       20/24                                            1.79 (0.96--3.34)                        0.068                         123/278                                          45/63                                    **1.61 (1.04--2.50)**        **0.032**                                        152/302                                  16/39                              0.83 (0.45--1.53)                                0.546                                    107/239   61/102   1.35 (0.91--1.99)   0.137
  Male              206/421                       19/48                                            0.83 (0.48--1.45)                        0.516                         179/359                                          46/110                                   0.85 (0.57--1.25)            0.398                                            198/422                                  27/47                              1.22 (0.74--2.02)                                0.442                                    151/312   74/157   0.98 (0.70--1.37)   0.899
  Sites of origin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Adrenal gland     140/738                       13/72                                            0.97 (0.52--1.80)                        0.915                         115/637                                          38/173                                   1.23 (0.82--1.84)            0.327                                            133/724                                  20/86                              1.24 (0.73--2.08)                                0.430                                    94/551    59/259   1.33 (0.93--1.90)   0.122
  Retroperitoneal   79/738                        8/72                                             1.01 (0.47--2.18)                        0.982                         67/637                                           20/173                                   1.08 (0.64--1.83)            0.776                                            82/724                                   5/86                               0.52 (0.21--1.32)                                0.169                                    62/551    25/259   0.85 (0.52--1.39)   0.516
  Mediastinum       98/738                        11/72                                            1.16 (0.59--2.27)                        0.661                         89/637                                           20/173                                   0.84 (0.50--1.40)            0.493                                            95/724                                   14/86                              1.25 (0.68--2.28)                                0.478                                    75/551    34/259   0.97 (0.63--1.50)   0.901
  Others            30/738                        6/72                                             2.00 (0.81--4.99)                        0.135                         24/637                                           12/173                                   1.82 (0.89--3.73)            0.100                                            34/724                                   2/86                               0.50 (0.12--2.13)                                0.350                                    22/551    14/259   1.35 (0.68--2.69)   0.391
  Clinical stage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  I+II+4s           146/738                       16/72                                            1.13 (0.64--2.00)                        0.677                         126/637                                          36/173                                   1.06 (0.70--1.59)            0.792                                            143/724                                  19/86                              1.13 (0.66--1.91)                                0.661                                    107/551   55/259   1.10 (0.77--1.57)   0.602
  III+IV            190/738                       21/72                                            1.17 (0.70--1.95)                        0.561                         160/637                                          51/173                                   1.19 (0.83--1.71)            0.335                                            187/724                                  24/86                              1.06 (0.65--1.71)                                0.821                                    135/551   76/259   1.20 (0.87--1.65)   0.259

Adjusted for age and sex.

Values in bold inidicate *P*\<0.05.

Discussion {#sec4}
==========

In the present study, we found the *H19* gene rs3024270 C\>G polymorphism was associated with neuroblastoma susceptibility in females. This is the first study to report an association between the rs3024270 GG genotype and an increased neuroblastoma risk in female Chinese children in a recessive model.

The association between these SNPs and cancer risk has been studied, while evidence of rs3024270 GG genotype and cancer risk are relatively limited. A study by Li et al. \[[@B20]\] reported an increased risk of colorectal cancer in a Chinese population with the rs3024270 GG genotype. A meta-analysis conducted by Lv et al. \[[@B21]\] investigated the association between long noncoding RNA polymorphisms and cancer risk, and the rs3024270 C\>G polymorphism was reported to be correlated with an overall cancer risk. However, another study found a decreased risk of invasive bladder cancer in patients with the rs3024270 CC genotype in the Chinese population \[[@B41]\]. Besides the rs3024270 C\>G polymorphism, a series of studies reported the role of the rs2839698 G\>A polymorphism in platinum-based chemotherapy response in lung cancer \[[@B42]\], colorectal cancer \[[@B20]\], gastric cancer \[[@B24]\] and rheumatoid arthritis \[[@B22]\]. The rs217727 G\>A polymorphism was also reported to be associated with a risk of oral squamous cell carcinoma \[[@B19]\], osteosarcoma \[[@B43]\], bladder cancer \[[@B44]\], cervical cancer of the squamous carcinomas subtype \[[@B20]\], and breast cancer \[[@B27]\]. Our study provides new evidence that the rs3024270 C\>G polymorphism in the *H19* gene might be involved in the development of neuroblastoma.

SNPs studied in our research are all located in the *H19* gene and were reported to have an impact on the folding structure of *H19* \[[@B20]\], which may affect the expression or functions of H19. The role of H19 in cancers has been widely studied. The *H19* gene is an imprinted oncofetal gene that is located on chromosome 11p15.5 near the *IGF2* gene locus \[[@B45]\]. Wada et al. \[[@B46]\] reported a maintenance of normal imprinting of the *H19* and *IGF2* genes in neuroblastoma. The expression of H19 was significantly up-regulated in hepatic metastases of several types of cancers \[[@B47]\]. Growing evidence indicates that H19 is involved in both the proliferation and differentiation processes of cancer cells. H19 promotes cell cycle progression in breast cancer, while the depletion of *H19* RNA arrests breast cancer cells in the pre-S-phase of the cell cycle \[[@B48]\]. The knockdown of H19 inhibits the growth of HCC and gastric cancer cells under hypoxic recovery conditions \[[@B49]\].

The mechanisms by which these SNPs regulate H19 expression and are involved in cancer are unclear. A possible explanation is that SNPs may affect *H19* gene expression and function. It was reported that rs3024270 C\>G, rs2839698 G\>A, and rs217727 G\>A dramatically altered the secondary structure of H19, and the rs3024270 GG genotype was associated with an increased risk of colorectal cancer in a Chinese population. H19 was found to act as a primary microRNA precursor, and H19 expression regulated specific mRNAs via post transcription \[[@B53]\]. Liang et al. \[[@B54]\] reported that lncRNA H19 modulated the expression of multiple genes involved in colorectal cancer by acting as a competing endogenous RNA, and H19 was also reported to produce antisense 91H, which increased the stability in cancer cells, leading to the accumulation of 91H in cancer cell lines and breast cancer tissues \[[@B55]\]. SNPs located in the introns and exons of the *H19* gene might change the promoter activity and function of H19 by the alteration of target miRNAs, such as hsa-miR-24-1-5p, hsa-miR-4486, and hsa-miR-566 \[[@B55]\]. Additionally, H19 was also found to interact with other tumor suppressor genes, such as *p53* and *c-Myc*. Increased expression of H19 during hypoxic conditions was found in cell lines with a mutant *p53* gene but not in cells with wild-type *p53* gene \[[@B50]\], and overexpression of H19 partially suppressed p53 activation in gastric cancer cells \[[@B51]\]. H19 expression was activated by c-Myc via direct binding to the regulatory region of the *H19* gene \[[@B52]\].

In our study, we found the GG allele pattern in 45/63 female NB patients and in 46/110 male NB patients. In the stratification analysis based on sex, disequilibrium of the G allele and the C allele was found. *H19* is an imprinted gene that is expressed from the maternal chromosome, but not the paternal chromosome \[[@B45]\]. This fact might partly explain the apparent disequilibrium of the analyzed SNPs. In the stratified analysis, no relation of H19 SNPs with the susceptibility of neuroblastoma patients, the origin of the tumor and the clinical stage of the tumor were found. In other studies, no relationship between rs3024270 and the susceptibility of cancer was found in stratified analyses, including age, sex, smoking, drinking etc. Further studies with larger sample sizes of patients with neuroblastoma and other tumors may provide more information.

There are several limitations of this case--control study. First, a potential selection bias would be induced because the enrollment of cases and controls occurred in a hospital. Therefore, further studies with larger populations would be of great value. Second, only three SNPs in the *H19* were included in the current study, and other polymorphisms, such as rs2735971 C\>T, were not included. Furthermore, the biological functions of the three SNPs are not clear, so functional studies are needed to provide more evidence. The sample size is relatively small in the present study due to the difficulty in sample collection. We will continue our study on neuroblastoma and update the results in further study.

Conclusion {#sec5}
==========

In the present study, we reported the relationship between the rs3024270 GG genotype and the increased susceptibility of neuroblastoma in female Chinese children. Further functional studies on rs3024270 and studies with larger populations and different ethnicities would be valuable to clarify the role of *H19* SNPs in neuroblastoma.
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